Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 2,700 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Jonathan Sheena sold 2,700 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the sale, the insider now owns 284,741 shares of the company's stock, valued at $36,324,409.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Jonathan Sheena also recently made the following trade(s):

• On Thursday, August 15th, Jonathan Sheena sold 12,000 shares of Natera stock. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00.
• On Monday, August 12th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $113.82, for a total transaction of $307,314.00.
• On Monday, July 1st, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $108.87, for a total transaction of $293,949.00.

Natera Stock Performance

Shares of Natera stock traded up $0.65 during trading on Friday, hitting $127.78. 2,190,370 shares of the stock were exchanged, compared to its average volume of 1,369,813. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The company has a fifty day moving average price of $114.45 and a 200-day moving average price of $105.31. The stock has a market capitalization of $15.69 billion, a price-to-earnings ratio of -40.96 and a beta of 1.53. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $132.01.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analysts' expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera's quarterly revenue was up 58.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.97) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of a number of research reports. Robert W. Baird increased their target price on Natera from $117.00 to $120.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. Piper Sandler reiterated an "overweight" rating and set a $150.00 price objective on shares of Natera in a report on Friday, September 13th. BTIG Research boosted their target price on Natera from $125.00 to $135.00 and gave the company a "buy" rating in a research note on Friday, August 9th. UBS Group decreased their price target on shares of Natera from $160.00 to $145.00 and set a "buy" rating for the company in a research note on Friday, August 9th. Finally, StockNews.com lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and an average price target of $120.07.

Institutional Investors Weigh In On Natera

Several hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. acquired a new stake in Natera during the second quarter worth approximately $28,000. Principal Securities Inc. bought a new position in shares of Natera during the fourth quarter worth approximately $32,000. Quarry LP lifted its holdings in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock worth $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC boosted its stake in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock valued at $35,000 after purchasing an additional 108 shares during the period. Finally, YHB Investment Advisors Inc. acquired a new position in Natera in the 1st quarter valued at $36,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.